Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01448291
Other study ID # CRC-NVR11
Secondary ID 11-01-FB-0003
Status Recruiting
Phase Phase 4
First received July 8, 2011
Last updated April 23, 2012
Start date October 2011
Est. completion date March 2013

Study information

Verified date April 2012
Source Eastern Virginia Medical School
Contact Julia Caul
Phone 7574465808
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

It is not known if the use of NuvaRing® alters these innate and inflammatory biomarkers of inflammation.

Hypothesis:

The hypothesis is that NuvaRing® will alter inflammatory biomarkers of inflammation, such as vaginal defensin and cytokine levels, resulting in an overall anti-inflammatory milieu in the vagina.

Specific aims of this study are to:

1. Determine biomarkers of inflammation, including defensins and cytokines, concentrations in women with normal vaginal flora (Nugent Score 0 - 3) before and after NuvaRing® use

2. Determine changes in the integrity of cervicovaginal epithelium and leukocytic concentration before and after treatment with NuvaRing®

3. Monitor for changes in the Nugent score before and after NuvaRing® use

4. Assess the antimicrobial activity of vaginal fluid before and after NuvaRing® use

5. Assess HIV infectivity ex vivo on biopsy specimens before and after NuvaRing® use

Methods This is a prospective, open-label, nonrandomized study. Participants will serve as their own controls. The Clinical Research Center of Eastern Virginia Medical School, Norfolk, Virginia, U.S.A. will be the only study site.


Description:

1. To complete specific aim #1, the investigators will use commercially available elisa kits to measure human defensins, inflammatory cytokines, and anti-inflammatory cytokines in vaginal fluid washings collected before and after use of NuvaRing.

2. To complete specific aim #2, the investigators will collect biopsies of the uterine cervix before and after NuvaRing use. Specimens will undergo histopathological measures for overall appearance, epithelial integrity, epithelial thickness, leukocyte infiltration, congestion, and edema. The investigators will quantitate the number of CD45+ and NFkB+ cells using immunohistology in the cervical epithelium.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 2013
Est. primary completion date October 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Women (age 18 - 45) interested in using NuvaRing® for contraception for 3 or more months, and women who are not at risk for pregnancy (i.e. abstinent, tubal sterilization, partner with vasectomy)

2. Women with a normal menstrual cycle (21-35 days) for the past three cycles

3. Women with normal pelvic anatomy (by physical exam)

4. Negative urine pregnancy test

5. Normal pap smear within the past 12 months

Exclusion Criteria:

1. Pregnancy

2. Current breastfeeding

3. Less than 6 weeks post partum

4. Current IUD or Implanon use

5. Depot Medroxyprogesterone Acetate use within the past 6 months

6. Current diagnosis of uterine infection

7. Use of hormonal contraception within the past 30 days

8. Current cervical dysplasia

9. Chronic immune suppression

10. Chronic use of immune suppressors such as steroids

11. Chronic antibiotic use

12. Diabetes or fasting blood glucose >105

13. Hysterectomy

14. Uncontrolled hypertension (systolic BP=140/ diastolic BP= 90)

15. Migraine headaches complicated by aura or focal neurologic deficits

16. Menopause

17. Standard contraindications to combined oral contraceptive use (thrombophilia, active liver disease, active deep venous thrombosis, history of thrombosis)

18. Use of tobacco products = 35 years of age

19. Two or more symptomatic genital herpes simplex virus (HSV) outbreaks in past 12 months

20. Human immunodeficiency virus

21. Vulvovaginal candidiasis

22. Trichamonas vaginalis

23. Neisseria gonorrhea

24. Chlamydia trachomatis

25. Bacterial vaginosis

26. Nugent scores of 4 or greater

27. Use of any other study medication within the past 30 days

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months

Locations

Country Name City State
United States Clinical Research Center at Eastern Virginia Medical School Norfolk Virginia

Sponsors (2)

Lead Sponsor Collaborator
Eastern Virginia Medical School Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States, 

References & Publications (5)

Cherpes TL, Marrazzo JM, Cosentino LA, Meyn LA, Murray PJ, Hillier SL. Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sex Transm Infect. 2008 Feb;84(1):57-61. Epub 2007 Oct 2. — View Citation

Fan SR, Liu XP, Liao QP. Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis. Int J Gynaecol Obstet. 2008 Oct;103(1):50-4. doi: 10.1016/j.ijgo.2008.05.020. Epub 2008 Jul 16. — View Citation

Iqbal SM, Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol. 2008 Jan;59(1):44-54. Review. — View Citation

John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, Wallenstein S, Carlucci MJ, Tuyama AC, Lu W, Klotman ME, Lehrer RI, Herold BC. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis. 2005 Nov 15;192(10):1731-40. Epub 2005 Oct 13. — View Citation

Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002 Sep;187(3):561-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Determine biomarkers of inflammation, including defensins and cytokines, concentrations in women with normal vaginal flora (Nugent Score 0 - 3) after 3 months of NuvaRing® use 3 months Yes
Secondary Determine changes in the integrity of cervicovaginal epithelium and leukocytic concentration after 3 months of treatment with NuvaRing® Baseline and 3 months Yes
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02558179 - Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method N/A
Completed NCT02272231 - Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
Completed NCT02314429 - Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis Phase 1
Completed NCT02139839 - Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14 Phase 0
Recruiting NCT03500107 - Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial N/A
Completed NCT00153517 - Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy Phase 2
Completed NCT04989543 - Study of the Composition and Bacterial Diversity of the Vaginal Microbiota in Healthy Versus Pathological Conditions (Bacterial Vaginosis) Using a Targeted Metagenomic Approach (RNA 16s) N/A
Completed NCT02641717 - Validity of Patient-Collected Wet Mounts N/A
Terminated NCT03943823 - Postmenopausal Pessary Users: Estrogen Versus Trimosan Phase 4
Completed NCT03134924 - Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention "WASH-2" N/A
Completed NCT01293643 - A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Phase 3
Terminated NCT01153958 - Colposeptine for the Treatment of Bacterial Vaginosis Phase 4
Completed NCT00484653 - Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman N/A
Completed NCT05649735 - EFFICACY AND SAFETY OF OVA AND LAVAGE MEDICAL DEVICES IN THE TREATMENT OF NON-SPECIFIC VULVOVAGINITIS N/A
Completed NCT02860845 - Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Phase 4
Not yet recruiting NCT00491270 - Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Phase 3
Completed NCT01055106 - Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis Phase 2
Terminated NCT01322971 - Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population N/A
Completed NCT04171947 - Vaginal Ovule With Flavonoid Tea Extract for the Correction of Imbalance in the Vaginal Environment N/A
Completed NCT02392026 - Safety and Tolerability of Metronidazole Gel 1.3% Phase 4